Skip to main
SMTI

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech Inc. exhibits a strong positive outlook due to significant year-over-year growth in its product lines, with sales of surgical soft tissue repair products reaching $23.4 million, reflecting a 24% increase driven by heightened demand for CellerateRX Surgical and BIASURGE. Additionally, the company reported a robust 28% increase in revenue for soft tissue repair products, further supporting its growth trajectory in the surgical segment. The strategic initiatives to expand distribution networks and penetrate additional healthcare facilities are expected to sustain this momentum, coupled with the notable achievement of profitability in continuing operations anticipated for the third quarter of 2025.

Bears say

Sanara MedTech Inc. reported net revenue of $26.3 million, indicating a 21.5% year-over-year growth that fell slightly short of projections, raising concerns about its revenue growth trajectory. Key risks identified include the potential for lower-than-expected revenue growth, challenges in acquiring new customers, difficulties in launching new products or services, and risks of equity dilution. Additionally, the company's valuation has been revised downwards, with the EV/Revenue multiple decreasing from 4.3x to 3.0x following the strategic decision to exclude telehealth from its business model.

SMTI has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Buy based on their latest research and market trends.

According to 2 analysts, SMTI has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.